The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial
Open accessAbstract
IMPORTANCE: Efficacious ERBB2 (formerly HER2 or HER2/neu)-directed treatments, in addition to trastuzumab and lapatinib, are needed. OBJECTIVE: To determine whether neratinib, an irreversible pan-ERBB tyrosine kinase inhibitor, plus paclitaxel improves progression-free survival compared with trastuzumab plus paclitaxel in the first-line treatment of recurrent and/or metastatic ERBB2-positive breast cancer. DESIGN, SETTING, AND PARTICIPANTS: In the randomized, controlled, open-label NEfERT-T trial conducted from August 2009 to December 2014 at 188 centers in 34 countries in Europe, Asia, Africa, and North America, 479 women with previously untreated recurrent and/or metastatic ERBB2-positive breast cancer were randomized to 1 of 2 treatment arms (neratinib-paclitaxel [n = 242] or trastuzumab-paclitaxel [n = 237]). Women with asymptomatic central nervous system metastases were eligible, and randomization was stratified by prior trastuzumab and lapatinib exposure, hormone-receptor status, and region. INTERVENTIONS: Women received neratinib (240 mg/d orally) or trastuzumab (4 mg/kg then 2 mg/kg weekly), each combined with paclitaxel (80 mg/m2 on days 1, 8, and 15 every 28 days). Primary prophylaxis for diarrhea was not mandatory. MAIN OUTCOME AND MEASURES: The primary outcome was progression-free survival. Secondary end points were response rate, clinical benefit rate, duration of response, frequency, and time to symptomatic and/or progressive central nervous system lesions, and safety. RESULTS: The intent-to-treat population comprised 479 women 18 years or older (neratinib-paclitaxel, n = 242; trastuzumab-paclitaxel, n = 237) randomized and stratified in their respective treatment arms by prior trastuzumab and lapatinib exposure, hormone-receptor status, and region. Median progression-free survival was 12.9 months (95% CI, 11.1-14.9) with neratinib-paclitaxel and 12.9 months (95% CI, 11.1-14.8) with trastuzumab-paclitaxel (hazard ratio [HR], 1.02; 95% CI, 0.81-1.27; P =.89). With neratinib-paclitaxel, the incidence of central nervous system recurrences was lower (relative risk, 0.48; 95% CI, 0.29-0.79; P = .002) and time to central nervous system metastases delayed (HR, 0.45; 95% CI, 0.26-0.78; P = .004). Common grade 3 to 4 adverse events were diarrhea (73 of 240 patients [30.4%] with neratinib-paclitaxel and 9 of 234 patients [3.8%] with trastuzumab-paclitaxel), neutropenia (31 patients [12.9%] vs 34 patients [14.5%]) and leukopenia (19 patients [7.9%] vs 25 patients [10.7%]); no grade 4 diarrhea was observed. CONCLUSIONS AND RELEVANCE: In first-line ERBB2-positive metastatic breast cancer, neratinib-paclitaxel was not superior to trastuzumab-paclitaxel in terms of progression-free survival. In spite of similar overall efficacy, neratinib-paclitaxel may delay the onset and reduce the frequency of central nervous system progression, a finding that requires a larger study to confirm. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00915018.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“Median (IQR) time to onset of grade 3 diarrhea was 16 (6-65) days, with a median (IQR) duration of 2 (1-3) days per event and 5 (3-9) days per patient (eTable 5 in Supplement 2).”
BackgroundA Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,960
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., Mackey, J., Glaspy, J., Chan, A., Pawlicki, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910383 · Cited by 2,775
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
Self-citationComprehensive analysis of kinase inhibitor selectivity
Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., & Zarrinkar, P. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1990 · Cited by 2,409
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413513 · Cited by 2,164
Self-citationEstimation of minimally important differences in EQ-5D utility and VAS scores in cancer
Pickard, A. S., Neary, M. P., & Cella, D. (2007) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-5-70 · Cited by 929
Cameron, D., Casey, M., Press, M., Lindquist, D., Pienkowski, T., Romieu, C. G., Chan, S., Jagiello-Gruszfeld, A., Kaufman, B., Crown, J., et al. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9885-0 · Cited by 794
Bachelot, T., Romieu, G., Campone, M., Diéras, V., Cropet, C., Dalenc, F., Jimenez, M., Le Rhun, E., Pierga, J.-Y., Gonçalves, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70432-1 · Cited by 737
Self-citationLin, N. U., Diéras, V., Paul, D., Lossignol, D., Christodoulou, C., Stemmler, H.-J., Roché, H., Liu, M. C., Greil, R., Ciruelos, E., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1080 · Cited by 658
Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase
Rabindran, S. K., Discafani, C. M., Rosfjord, E. C., Baxter, M., Floyd, M. B., Golas, J., Hallett, W. A., Johnson, B. D., Nilakantan, R., Overbeek, E., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2868 · Cited by 639
Burstein, H. J., Sun, Y., Dirix, L. Y., Jiang, Z., Paridaens, R., Tan, A. R., Awada, A., Ranade, A., Jiao, S., Schwartz, G., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.8707 · Cited by 522
Self-citationGoldhirsch, A., Gelber, R. D., Piccart-Gebhart, M. J., de Azambuja, E., Procter, M., Suter, T. M., Jackisch, C., Cameron, D., Weber, H. A., Heinzmann, D., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61094-6 · Cited by 497
Robert, N., Leyland-Jones, B., Asmar, L., Belt, R., Ilegbodu, D., Loesch, D., Raju, R., Valentine, E., Sayre, R., Cobleigh, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.1764 · Cited by 479
de Azambuja, E., Holmes, A. P., Piccart-Gebhart, M., Holmes, E., Di Cosimo, S., Swaby, R. F., Untch, M., Jackisch, C., Lang, I., Smith, I., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70320-1 · Cited by 458
Self-citationUntch, M., Loibl, S., Bischoff, J., Eidtmann, H., Kaufmann, M., Blohmer, J.-U., Hilfrich, J., Strumberg, D., Fasching, P. A., Kreienberg, R., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70397-7 · Cited by 451
Krop, I. E., Lin, N. U., Blackwell, K., Guardino, E., Huober, J., Lu, M., Miles, D., Samant, M., Welslau, M., & Diéras, V. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu486 · Cited by 394
Eton, D. T., Cella, D., Yost, K. J., Yount, S. E., Peterman, A. H., Neuberg, D. S., Sledge, G. W., & Wood, W. C. (2004) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2004.01.012 · Cited by 390
Andersson, M., Lidbrink, E., Bjerre, K., Wist, E., Enevoldsen, K., Jensen, A. B., Karlsson, P., Tange, U. B., Sørensen, P. G., Møller, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.8213 · Cited by 294
Effect of Lapatinib on the Outgrowth of Metastatic Breast Cancer Cells to the Brain
Gril, B., Palmieri, D., Bronder, J. L., Herring, J. M., Vega-Valle, E., Feigenbaum, L., Liewehr, D. J., Steinberg, S. M., Merino, M. J., Rubin, S. D., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn216 · Cited by 283
Valero, V., Forbes, J., Pegram, M. D., Pienkowski, T., Eiermann, W., von Minckwitz, G., Roche, H., Martin, M., Crown, J., Mackey, J. R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.6450 · Cited by 255
Gianni, L., Romieu, G. H., Lichinitser, M., Serrano, S. V., Mansutti, M., Pivot, X., Mariani, P., Andre, F., Chan, A., Lipatov, O., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.7912 · Cited by 254
Polli, J. W., Humphreys, J. E., Harmon, K. A., Castellino, S., O’Mara, M. J., Olson, K. L., John-Williams, L. S., Koch, K. M., & Serabjit-Singh, C. J. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.018374 · Cited by 243
Pivot, X., Manikhas, A., Żurawski, B., Chmielowska, E., Karaszewska, B., Allerton, R., Chan, S., Fabi, A., Bidoli, P., Gori, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.1794 · Cited by 242 · cited 1×
“Median (IQR) time to onset of grade 3 diarrhea was 16 (6-65) days, with a median (IQR) duration of 2 (1-3) days per event and 5 (3-9) days per patient (eTable 5 in Supplement 2).”
BackgroundSwain, S. M., Baselga, J., Miles, D., Im, Y.-H., Quah, C., Lee, L. F., & Cortés, J. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu133 · Cited by 232
Pestalozzi, B. C., Holmes, E., de Azambuja, E., Metzger-Filho, O., Hogge, L., Scullion, M., Láng, I., Wardley, A., Lichinitser, M., Sanchez, R. I. L., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70017-2 · Cited by 210
Piccart, M. J., Holmes, A., Baselga, J. M., de Azambuja, E., Dueck, A. C., Viale, G., Zujewski, J. A., Goldhirsch, A., Santillana, S., Pritchard, K. I., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.18_suppl.lba4 · Cited by 154
Guan, Z., Xu, B., DeSilvio, M., Shen, Z., Arpornwirat, W., Tong, Z., Lorvidhaya, V., Jiang, Z., Yang, J., Makhson, A. N., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.5241 · Cited by 141
Olson, E. M., Najita, J., Sohl, J. J., Arnaout, A., Burstein, H. J., Winer, E. P., & Lin, N. (2013) · The Breast · doi:10.1016/j.breast.2012.12.006 · Cited by 128
Wardley, A. M., Pivot, X. B., Morales-Vásquez, F., Zetina, L. M., Gauí, M. D. F. D., Reyes, D. O., Jassem, J., Barton, C. M., Button, P., Hersberger, V., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6531 · Cited by 127
Baselga, J. M., Manikhas, A., Cortés, J., Llombart‐Cussac, A., Roman, L., Семиглазов, В. Ф., Byakhov, M. J., Lokanatha, D., Forenza, S., Goldfarb, R. H., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt543 · Cited by 100
Inoue, K., Nakagami, K., Mizutani, M., Hozumi, Y., Fujiwara, Y., Masuda, N., Tsukamoto, F., Saito, M., Miura, S., Eguchi, K., et al. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0498-7 · Cited by 89
Self-citationChow, L. W., Xu, B., Gupta, S., Freyman, A., Zhao, Y., Abbas, R., Van, M.-L. V., & Bondarenko, I. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.178 · Cited by 84
Self-citationBesse, B., Soria, J., Yao, B., Kris, M. G., Chao, B. H., Cortot, A. B., Mazières, J., Socinski, M. A., Horn, L., Waqar, S. N., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu438.47 · Cited by 44
Self-citationGenomic Alterations in Patients Showing Multiple Primary Tumors and Family History of Cancer
do Canto, L. M., Basso, T. R., Villacis, R. A. R., Giacomazzi, J., Ashton‐Prolla, P., Achatz, M. I., & Rogatto, S. R. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu332.4 · Cited by 39
Cited by
Loibl, S., Poortmans, P., Morrow, M., Denkert, C., & Curigliano, G. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32381-3 · Cited by 1,648
Loibl, S., & Gianni, L. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32417-5 · Cited by 1,116
Saura, C., Oliveira, M., Feng, Y.-H., Dai, M.-S., Chen, S.-W., Hurvitz, S. A., Kim, S.-B., Moy, B., Delaloge, S., Gradishar, W., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00147 · Cited by 604
Self-citationChan, A., Delaloge, S., Holmes, F. A., Moy, B., Iwata, H., Harvey, V. J., Robert, N. J., Silovski, T., Gokmen, E., von Minckwitz, G., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00551-3 · Cited by 561
Self-citationHER2-positive breast cancer: new therapeutic frontiers and overcoming resistance
Pernas, S., & Tolaney, S. M. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919833519 · Cited by 348
Metadata
- Authors
- Awada, A., Colomer, R., Inoue, K., Bondarenko, I., Badwe, R. A., Demetriou, G., Lee, S.-C., Mehta, A. O., Kim, S.-B., Bachelot, T., Goswami, C., Deo, S., Bose, R., Wong, A., Xu, F., Yao, B., Bryce, R., & Carey, L. A.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2016-12-01
- Volume
- 2
- Issue
- 12
- Pages
- 1557
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W2338611117
- Cited by
- 305
- References
- 36
- FWCI
- 13.44
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.